Targeting FcRH5 in MM: Rationale and emerging dual-targeting strategies
The Multiple Myeloma Hub was pleased to speak with Adam Cohen, University of Pennsylvania, Philadelphia, US. We asked about the rationale for targeting FcRH5 in multiple myeloma and emerging dual-targeting strategies.
In this interview, Cohen discusses Fc receptor-homolog 5 (FcRH5) as a therapeutic target in multiple myeloma (MM) and its potential role following antigen loss associated with B-cell maturation antigen (BCMA)- or G protein-coupled receptor class C group 5 member D (GPRC5D)-directed therapy. Cohen outlines the rationale for targeting multiple antigens, the potential benefits and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.